Insider Trading November 19, 2026 12:31 AM

LifeStance Director Burdick Offloads $1.78M in Stock as Shares Near 52-Week High

The sale of 124,228 shares comes after a 123% rally in LifeStance Health Group's stock over the past year.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
LFST

Kenneth A. Burdick, a director at LifeStance Health Group, sold 124,228 shares for approximately $1,777,702 on November 16, 2026, at a weighted average price of $14.31. The transaction follows a 123% surge in LifeStance shares over the past year, with the stock trading near its 52-week high of $15.66. Following the sale, Burdick directly holds 3,472,038 shares and indirectly owns 46,511 shares through Burdick Family LLC. The company recently reported strong third-quarter 2026 earnings, beating Wall Street estimates and prompting BMO Capital to raise its price target to $16.00 from $13.00 while maintaining an Outperform rating. LifeStance also raised its full-year outlook for revenue, center margin, and adjusted EBITDA.

LifeStance Director Burdick Offloads $1.78M in Stock as Shares Near 52-Week High
LFST
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Kenneth A. Burdick sold 124,228 shares for approximately $1.78 million at a weighted average price of $14.31, following a 123% rally in LifeStance stock over the past year.
  • The sale occurred after LifeStance reported strong third-quarter 2026 results, with revenue of $455.86 million and adjusted EBITDA of $68 million, beating analyst estimates.
  • BMO Capital raised its price target to $16.00 from $13.00 and maintained an Outperform rating, citing revenue and EBITDA beats.
  • LifeStance raised its full-year outlook for revenue, center margin, and adjusted EBITDA, signaling confidence in continued growth.

Kenneth A. Burdick, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), has sold a substantial block of the company's common stock, according to a filing with the U.S. Securities and Exchange Commission. The transaction, executed on November 16, 2026, involved the disposition of 124,228 shares, generating proceeds of approximately $1,777,702.

The shares were sold at prices ranging from $14.30 to $14.33, with a weighted average price of $14.31 per share. The sale arrives on the heels of a remarkable run for LifeStance stock, which has climbed 123% over the past year and is trading near its 52-week high of $15.66. Year-to-date, the stock has gained 96%, and analysis indicates shares are trading close to Fair Value.

Following this transaction, Burdick directly holds 3,472,038 shares of LifeStance Health Group common stock. In addition, he indirectly beneficially owns 46,511 shares through Burdick Family LLC.

The insider sale comes amid a period of strong operational performance for LifeStance. In its third-quarter 2026 earnings report, the company delivered adjusted earnings of $0.06 per share on revenue of $455.86 million, surpassing Wall Street forecasts of $0.04 per share and $431.6 million in revenue. This marked a 25% increase in revenue from the previous year and the second consecutive quarter of such growth. Adjusted EBITDA also rose 70% to $68 million, maintaining a margin of 15% of revenue.

Encouraged by these results, LifeStance Health raised its full-year outlook for revenue, center margin, and adjusted EBITDA. BMO Capital responded by lifting its price target for LifeStance Health to $16.00 from $13.00, while keeping an Outperform rating. The firm highlighted the company's third-quarter performance, noting that revenue came in 5.6% above consensus estimates and EBITDA surpassed expectations by 23.6%. LifeStance Health's management also increased its full-year revenue and EBITDA outlook by 2.7% and 9.3%, respectively.

The stock closed at $13.77 on November 18, down $0.40 or 2.82%, and edged slightly lower in after-hours trading to $13.76, a decline of $0.01 or 0.07%.

Investors seeking deeper insights into LifeStance Health Group can access comprehensive research reports, which are available for LFST and over 1,400 other US equities.

Risks

  • Insider selling could be perceived negatively by investors, potentially signaling a lack of confidence in the stock's future prospects, especially after a significant run-up.
  • The stock's high valuation, trading near its 52-week high and close to Fair Value, may limit upside potential and increase vulnerability to market corrections.
  • Execution risks remain as the company must deliver on its raised full-year guidance, and any shortfall could impact investor sentiment.

More from Insider Trading

VSE Corp CEO John Cuomo Offloads $338,964 in Stock Under Pre-Arranged Plan Nov 19, 2026 Morningstar's Mansueto Offloads $1.8 Million in Shares Near 52-Week High Nov 19, 2026 Motorsport Games CFO Peter Hansen-Chambers Discloses $9,793 Share Purchase Nov 19, 2026 Peoples Bancorp Director Adds 200 Shares in Open-Market Purchase Nov 19, 2026 Atara Bio CEO Offloads $39,368 in Shares to Cover Tax Bill Nov 19, 2026